Investing

AI could deliver bioweapons capabilities to bad actors, safety chief warns: ‘Grave threat’

The CEO of an artificial intelligence ‘safety and research company’ warned the Senate Tuesday that AI could be just a few years away from giving bad actors around the globe the capacity to carry out biological weapons attacks.

Dario Amodei, CEO of Anthropic, told a Senate Judiciary subcommittee that the prospect of AI helping people develop and deliver these weapons is a medium-term risk that his company is grappling with today.

‘Over the last six months, Anthropic, in collaboration with world-class biosecurity experts, has conducted an intensive study on the potential for AI to contribute to the misuse of biology,’ he said.

‘Today, certain steps in bioweapons production involve knowledge that can’t be found on Google or in textbooks and requires a high level of specialized expertise — this being one of the things that currently keeps us safe from attacks,’ he added.

He said today’s AI tools can help fill in ‘some of these steps,’ though they can do this ‘incompletely and unreliably.’ But he said today’s AI is already showing these ‘nascent signs of danger,’ and said his company believes it will be much closer just a few years from now.

‘A straightforward extrapolation of today’s systems to those we expect to see in two to three years suggests a substantial risk that AI systems will be able to fill in all the missing pieces, enabling many more actors to carry out large-scale biological attacks,’ he said. ‘We believe this represents a grave threat to U.S. national security.’

Amodei added that Anthropic has briefed government officials on this assessment, ‘all of whom found the results disquieting.’

While his company supports the safe developing of AI, he said this dangerous risk posed by AI won’t go away because of corporate actions alone.

‘Private action is not enough,’ he said. ‘This risk and many others like it requires a systemic policy response.’

Amodei suggested three steps for the government to take, and outlined those steps in the Senate hearing that was aimed at sorting out the ‘principles’ of AI regulation. First, he said the government should take steps to put limits on the export of equipment that can help people develop AI systems.

‘The U.S. must secure the AI supply chain in order to maintain its lead while keeping these technologies out of the hands of bad actors,’ he said.

He also recommended a tough testing and auditing regime for all powerful, new AI models, and said those models shouldn’t be released to the public until they pass those tests. And third, he said more work needs to be done testing the systems used to audit AI tools.

‘It is not currently easy to detect all the bad behaviors an AI system is capable of without first broadly deploying it to users, which is what creates the risk,’ he said.

Amodei’s company is one of seven that agreed last week to a set of guidelines promoted by the White House that are aimed at developing safe, secure and trustworthy AI tools.

Amodei was at the White House last week as Biden announced the initiative, along with representatives from Amazon, Google, Inflection, Meta, Microsoft and OpenAI.

This post appeared first on FOX NEWS

You May Also Like

Editor's Pick

ERP or Enterprise Resource Planning solutions help businesses of all sizes manage their daily business operations. First used in the 1990s, ERP systems have...

Investing

Democratic Gov. Janet Mills on Wednesday vetoed a bill aimed at prohibiting foreign influence in Maine elections, but voters will get the final say...

Latest News

There were several reasons offered in support of the congestion pricing plan that was supposed to go into effect in New York at the...

Latest News

House Speaker Mike Johnson (R-La.) on Wednesday appointed Reps. Scott Perry (R-Pa.) and Ronny Jackson (R-Tex.), two Trump loyalists who denied the results of...

Disclaimer: realinvestmentstar.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 realinvestmentstar.com